1. In this randomized control trial, an eight-week bedaquiline-linezolid regimen was noninferior to standard 24-week treatment for tuberculosis. 2. The ...
1. In this randomized control trial, an eight-week bedaquiline-linezolid regimen was noninferior to standard 24-week treatment for tuberculosis. 2. The ...
![Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/TB-original-e1591582219420-350x250.jpg)
1. A 24-week regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) resulted in lower mortality, treatment failure, and discontinuation compared ...
1. At 24 months, treatment success rate was numerically greater in the shorter-regimen group versus conventional therapy, satisfying the noninferiority ...
1. At 24 months, treatment success rate was numerically greater in the shorter-regimen group versus conventional therapy, satisfying the noninferiority ...
1. Four bedaquiline-pretomanid-linezolid treatment groups had a favorable outcome for the treatment of drug-resistant tuberculosis. 2. The treatment group with ...
1. Afabicin, a novel, narrow-spectrum antibiotic, was found to be non-inferior to vancomycin and linezolid in treating staphylococcal skin and ...
![Weekly dalbavancin noninferior to daily therapy for acute skin infection [DISCOVER 1 and 2 Trials]](https://www.2minutemedicine.com/wp-content/uploads/2014/06/MRSA-aureus-350x250.jpg)
1. Once-weekly dalbavancin was not inferior to twice-daily vancomycin and linezolid in treating acute bacterial skin infection. 2. Fewer adverse ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
